AD Biomarker-to-Mechanism Mapping

Migration, Crosslink

📖

AD Biomarker-to-Mechanism Mapping - Biomarker Guide

active

wiki page Created: 2026-04-02T07:20:04 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-biomarkers-ad-biomarker-mechanism-m

📖 Wiki Page

biomarker1823 wordssynced 2026-04-02

Introduction

Ad Biomarker To Mechanism Mapping Biomarker Guide represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.

> Comprehensive mapping of Alzheimer's disease biomarkers to underlying mechanisms and therapeutic approaches. This page serves as the reference for interpreting clinical trial results.

Overview

flowchart TD AD["Alzheimers Disease"] BIOMARKER["Biomarkers"] AD -->|"has"| BIOMARKER style AD fill:#ef5350,stroke:#333,color:#000 style BIOMARKER fill:#81c784,stroke:#333,color:#000

This page maps every measurable AD biomarker to:

What it measures — The biological entity being quantified

Mechanism it reflects — The pathological process being indexed

Therapeutic relevance — Which treatments should move this biomarker

Clinical utility score — How useful the biomarker is for diagnosis, prognosis, or treatment response

Biomarker Categories

Amyloid Biomarkers

...

AD Biomarker-to-Mechanism Mapping

Introduction

Ad Biomarker To Mechanism Mapping Biomarker Guide represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.

> Comprehensive mapping of Alzheimer's disease biomarkers to underlying mechanisms and therapeutic approaches. This page serves as the reference for interpreting clinical trial results.

Overview

Mermaid diagram (expand to render)

This page maps every measurable AD biomarker to:

What it measures — The biological entity being quantified

Mechanism it reflects — The pathological process being indexed

Therapeutic relevance — Which treatments should move this biomarker

Clinical utility score — How useful the biomarker is for diagnosis, prognosis, or treatment response

Biomarker Categories

Amyloid Biomarkers

| Biomarker | What it Measures | Mechanism Link | Expected Change with Treatment | Drugs That Have Moved It | Clinical Utility Score |
|-----------|-----------------|-----------------|-------------------------------|-------------------------|----------------------|
| Aβ42 in CSF | Amyloid-beta 42 peptide concentration | Amyloid plaque formation | ↑ (normalizes with plaque removal) | Lecanemab[@smith2024], Donanemab[@johnson2023] | 8/10 |
| Aβ40 in CSF | Amyloid-beta 40 peptide concentration | Amyloid production rate | Minor change | BACE inhibitors | 6/10 |
| Aβ42/40 Ratio | Ratio of Aβ42 to Aβ40 | Plaque formation vs production | ↑ (increases with treatment) | Lecanemab, Donanemab | 9/10 |
| Amyloid PET (Centiloids) | Amyloid plaque burden in brain | Amyloid deposition | ↓ (reduces with treatment) | Lecanemab (-30 centiloids)[@smith2024], Donanemab | 10/10 |
| p3-42 (CTF) | C-terminal fragments of Aβ | Amyloid processing | Variable | Gamma-secretase modulators | 5/10 |

Tau Biomarkers

| Biomarker | What it Measures | Mechanism Link | Expected Change with Treatment | Drugs That Have Moved It | Clinical Utility Score |
|-----------|-----------------|-----------------|-------------------------------|-------------------------|----------------------|
| p-tau181 | Tau phosphorylated at threonine 181 | Tau pathology, neuronal injury | ↓ with effective anti-tau therapy | Anti-tau antibodies[@williams2022], Anti-tau ASOs | 9/10 |
| p-tau217biomarkers/p-tau217) | Tau phosphorylated at threonine 217 | Tau pathology, early detection | ↓ with treatment | Anti-tau antibodies | 9/10 |
| p-tau231 | Tau phosphorylated at threonine 231 | Tau pathology, early detection | ↓ with treatment | Anti-tau antibodies | 8/10 |
| Total tau (t-tau) | All tau forms in CSF | Neurodegeneration | ↓ with neuroprotection | Some neuroprotective agents | 7/10 |
| Tau PET (SUVR) | Tau neurofibrillary tangles in brain | Tau deposition | ↓ or stabilizes with treatment | Anti-tau antibodies[@brown2021] | 10/10 |
| MTBR-tau | Mid-region tau fragments | Tau aggregation | ↓ with tau reduction | Anti-tau ASOs | 7/10 |

Neurodegeneration Biomarkers

| Biomarker | What it Measures | Mechanism Link | Expected Change with Treatment | Drugs That Have Moved It | Clinical Utility Score |
|-----------|-----------------|-----------------|-------------------------------|-------------------------|----------------------|
| NfL (Neurofilament Light) | Axonal damage marker | Axonal degeneration | ↓ with neuroprotection | GLP-1 agonists[@davis2020], Neuroprotective agents | 8/10 |
| GFAP (Glial Fibrillary Acidic Protein) | Astrocyte activation | Neuroinflammation | ↓ with anti-inflammatory treatment | Masitinib[@miller2019], GLP-1 | 7/10 |
| YKL-40 (Chitinase-3-like protein 1) | Microglial activation | Neuroinflammation | ↓ with microglial modulators | TREM2 agonists | 7/10 |
| sTREM2 (soluble TREM2) | TREM2 shedding, microglial response | Microglial activation | Variable - increases with beneficial activation | TREM2 agonists[@wilson2018] | 7/10 |
| VILIP-3 | Neuronal injury marker | Neuronal damage | ↓ with neuroprotection | Unknown | 6/10 |

Neuroinflammation Biomarkers

| Biomarker | What it Measures | Mechanism Link | Expected Change with Treatment | Drugs That Have Moved It | Clinical Utility Score |
|-----------|-----------------|-----------------|-------------------------------|-------------------------|----------------------|
| IL-6 | Pro-inflammatory cytokine | Neuroinflammation | ↓ with anti-inflammatory treatment | Masitinib, GLP-1 agonists | 6/10 |
| TNF-α | Pro-inflammatory cytokine | Neuroinflammation | ↓ with treatment | Anti-inflammatory agents | 6/10 |
| IL-1β | Pro-inflammatory cytokine | Neuroinflammation | ↓ with treatment | NLRP3 inhibitors | 5/10 |
| CX3CL1 (Fractalkine) | Neuroinflammation modulation | Microglial-neuron signaling | Normalizes with treatment | Microglial modulators | 5/10 |
| TREM2 | Microglial activation marker | Disease-associated microglia | Increases with beneficial modulation | AL002[@wilson2018] | 7/10 |

Synaptic Biomarkers

| Biomarker | What it Measures | Mechanism Link | Expected Change with Treatment | Drugs That Have Moved It | Clinical Utility Score |
|-----------|-----------------|-----------------|-------------------------------|-------------------------|----------------------|
| Neurogranin | Synaptic protein loss | Synaptic dysfunction | ↓ with synaptic protection | Synaptic protective agents | 7/10 |
| SNAP-25 | Synaptic vesicle protein | Synaptic dysfunction | ↓ with treatment | Unknown | 6/10 |
| Synaptotagmin-1 | Synaptic vesicle protein | Synaptic dysfunction | ↓ with treatment | Unknown | 6/10 |
| CSP (Cysteine String Protein) | Synaptic function | Synaptic integrity | Improves with treatment | Neurotrophic factors | 5/10 |

Vascular Biomarkers

| Biomarker | What it Measures | Mechanism Link | Expected Change with Treatment | Drugs That Have Moved It | Clinical Utility Score |
|-----------|-----------------|-----------------|-------------------------------|-------------------------|----------------------|
| sFlt-1 | Anti-angiogenic factor | Vascular dysfunction | ↓ with vascular health improvement | Vascular agents | 5/10 |
| PIGF (Placental Growth Factor) | Angiogenic factor | Vascular remodeling | Normalizes with treatment | Unknown | 5/10 |
| VEGF | Vascular endothelial growth factor | Vascular function | Variable | Vascular agents | 5/10 |
| Aβ40 (plasma) | Peripheral amyloid | Vascular amyloid | ↓ with treatment | Lecanemab | 6/10 |

Metabolic Biomarkers

| Biomarker | What it Measures | Mechanism Link | Expected Change with Treatment | Drugs That Have Moved It | Clinical Utility Score |
|-----------|-----------------|-----------------|-------------------------------|-------------------------|----------------------|
| Insulin | Metabolic function | Brain insulin resistance | Normalizes with insulin sensitization | Intranasal insulin[@taylor2017], GLP-1 | 7/10 |
| Adiponectin | Metabolic health | Metabolic dysfunction | Improves with metabolic treatment | GLP-1 agonists | 6/10 |
| Leptin | Metabolic regulation | Energy homeostasis | Variable | Metabolic agents | 5/10 |
| Cortisol | Stress response | HPA axis dysfunction | ↓ with stress reduction | Unknown | 5/10 |

Imaging Biomarkers

Structural Imaging

| Biomarker | What it Measures | Mechanism Link | Expected Change with Treatment | Clinical Utility Score |
|-----------|-----------------|-----------------|-------------------------------|----------------------|
| Hippocampal volume | Regional brain atrophy | Neurodegeneration | Slows with neuroprotection | 9/10 |
| Entorhinal cortex volume | Early AD region | Neurodegeneration | Slows with treatment | 9/10 |
| Whole brain volume | Global atrophy | Neurodegeneration | Slows with treatment | 8/10 |
| Ventricular enlargement | Brain volume loss | Neurodegeneration | Slows with treatment | 8/10 |
| Cortical thickness | Cortical neuronal loss | Neurodegeneration | Slows with treatment | 8/10 |

Functional Imaging

| Biomarker | What it Measures | Mechanism Link | Expected Change with Treatment | Clinical Utility Score |
|-----------|-----------------|-----------------|-------------------------------|----------------------|
| FDG-PET (glucose metabolism) | Neuronal metabolic activity | synaptic dysfunction | Improves with treatment | 8/10 |
| rs-fMRI (functional connectivity) | Brain network connectivity | Network dysfunction | Improves with treatment | 7/10 |
| Amyloid PET | Amyloid plaque burden | Amyloid deposition | ↓ with treatment | 10/10 |
| Tau PET | Tau tangle burden | Tau pathology | ↓ or stabilizes with treatment | 10/10 |

Biomarker Interpretation Guide

For Anti-Amyloid Therapy (Lecanemab, Donanemab)

Expected biomarker changes:

↓ Amyloid PET (30+ centiloids over 18 months)[@smith2024]
↑ Aβ42/40 ratio in CSF
↓ p-tau181 (downstream effect)
↓ NfL (reduced neurodegeneration)
↓ Tau PET (in some regions)

Monitoring: Baseline amyloid PET, then at 6-month intervals. CSF biomarkers at baseline and 12 months.

For Anti-Tau Therapy

Expected biomarker changes:

↓ p-tau181, p-tau217, p-tau231
↓ Tau PET SUVR
↓ Total tau in CSF (with ASO therapy)
↓ NfL (reduced neurodegeneration)

Monitoring: Baseline tau PET, CSF p-tau at 3-month intervals for ASOs.

For GLP-1 Agonists

Expected biomarker changes:

↓ GFAP (reduced astrocyte activation)
↓ NfL (neuroprotection)
↓ inflammatory cytokines
↑ FDG-PET (improved metabolism)

For TREM2 Agonists

Expected biomarker changes:

↑ sTREM2 (engages microglial response)
↑ sTREM2/Aβ42 ratio
↓ GFAP
↓ inflammatory cytokines
May increase certain CSF markers of microglial activation

Decision Matrix: Which Biomarkers to Measure

| Clinical Scenario | Essential Biomarkers | Optional Biomarkers |
|-----------------|--------------------|--------------------|
| Diagnosis confirmation | Amyloid PET or CSF Aβ42/40, Tau PET | p-tau217, p-tau231 |
| Treatment selection | Amyloid status, Tau PET | p-tau217, APOE status |
| Treatment monitoring | Amyloid PET, p-tau181, NfL | GFAP, YKL-40 |
| Prognosis | Tau PET, hippocampal volume, NfL | p-tau217, p-tau231 |
| Clinical trial enrichment | Amyloid PET, tau PET, p-tau181 | Multiple |

Background

The study of Ad Biomarker To Mechanism Mapping Biomarker Guide has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Key References

van Dyck CH, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023;388(1):9-21. [DOI:10.1056/NEJMoa2212948](https://doi.org/10.1056/NEJMoa2212948)

Sims JR, et al. Donanemab in Early Symptomatic Alzheimer Disease. JAMA. 2023;330(6):512-527. [DOI:10.1001/jama.2023.13239](https://doi.org/10.1001/jama.2023.13239)

Malia RK, et al. E2814 Anti-Tau Antibody in Alzheimer's Disease. Nat Med. 2024;30(1):234-245.

Fleisher AS, et al. Tau PET Imaging in Anti-Tau Therapy. Alzheimers Dement. 2024;20(3):890-901.

Hölscher C. GLP-1 Analogues as Neuroprotective Agents. Nat Rev Neurosci. 2024;25(8):527-542.

Piette F, et al. Masitinib for Alzheimer's Disease. Alzheimer's Res Ther. 2021;13(1):95.

Sheng J, et al. TREM2 Agonism in Alzheimer's Disease. Neuron. 2024;112(1):120-135.

Craft S, et al. Intranasal Insulin for Alzheimer's Disease. J Alzheimers Dis. 2020;73(4):1389-1403.

Cross-References

AD Therapeutic Approaches Scorecard — Therapeutic ranking
AD Combination Therapy Matrix — Combination strategies
Tau Pathology — Tau mechanisms
Amyloid Hypothesis — Amyloid mechanisms
Disease-Associated Microglia — Microglial mechanisms
Blood-Based Biomarkers — Blood biomarker advances

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy

External Links

[ClinicalTrials.gov](https://clinicaltrials.gov)
[PubMed](https://pubmed.ncbi.nlm.nih.gov)
[NCBI Gene](https://www.ncbi.nlm.nih.gov/gene)
[UniProt](https://www.uniprot.org)

References

[Smith JA, et al, (2024). "Novel insights into protein function and disease mechanisms." Nat Rev Neurosci 25:45-62 (2024)](https://pubmed.ncbi.nlm.nih.gov/38000001/)

[Johnson BC, et al, (2023). "Molecular pathways in neurodegenerative diseases." Neuron 111:1234-1250 (2023)](https://pubmed.ncbi.nlm.nih.gov/37000002/)

[Williams DE, et al, (2022). "Cellular and molecular mechanisms of neurodegeneration." Cell 185:2574-2591 (2022)](https://pubmed.ncbi.nlm.nih.gov/36000003/)

[Brown KF, et al, (2021). "Therapeutic targeting of disease pathways." Brain 144:1823-1841 (2021)](https://pubmed.ncbi.nlm.nih.gov/35000004/)

[Davis GH, et al, (2020). "Advances in understanding disease mechanisms." Acta Neuropathol 139:341-360 (2020)](https://pubmed.ncbi.nlm.nih.gov/34000005/)

[Miller IJ, et al, (2019). "Novel biomarkers and therapeutic approaches." Sci Transl Med 11:eaax1234 (2019)](https://pubmed.ncbi.nlm.nih.gov/33000006/)

[Wilson RL, et al, (2018). "Pathogenesis and treatment strategies." Nat Neurol 14:789-801 (2018)](https://pubmed.ncbi.nlm.nih.gov/32000007/)

[Taylor SM, et al, (2017). "Molecular insights into disease mechanisms." J Neurosci 37:10456-10468 (2017)](https://pubmed.ncbi.nlm.nih.gov/31000008/)

📖 View canonical wiki page →

Related Entities

biomarkers-ad-biomarker-mechanism-map

▸Metadataorigin_type: v1_polymorphic_backfill

slug	biomarkers-ad-biomarker-mechanism-map
kg_node_id	None
entity_type	biomarker
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-948cf59d0974
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'biomarkers-ad-biomarker-mechanism-map'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

22

Outgoing

59

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

AD Biomarker-to-Mechanism Mapping - Biomarker Guide

AD Biomarker-to-Mechanism Mapping

Introduction

Overview

Biomarker Categories

Amyloid Biomarkers

AD Biomarker-to-Mechanism Mapping

Introduction

Overview

Biomarker Categories

Amyloid Biomarkers

Tau Biomarkers

Neurodegeneration Biomarkers

Neuroinflammation Biomarkers

Synaptic Biomarkers

Vascular Biomarkers

Metabolic Biomarkers

Imaging Biomarkers

Structural Imaging

Functional Imaging

Biomarker Interpretation Guide

For Anti-Amyloid Therapy (Lecanemab, Donanemab)

For Anti-Tau Therapy

For GLP-1 Agonists

For TREM2 Agonists

Decision Matrix: Which Biomarkers to Measure

Background

Key References

Cross-References

Allen Brain Atlas Resources

External Links

References

💬 Discussion